CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Epithelial Cell Cytology in Breast Cancer Risk Assessment

Covers nipple aspiration, ductal lavage, and fine needle aspiration cytologic analysis of epithelial cells for evaluation of nipple discharge and breast cancer risk; defines coverage stance and applicable procedure codes for Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyEpithelial Cell Cytology in Breast Cancer Risk Assessment

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDo not submit prior authorization for cytologic analysis to assess breast cancer risk — this indication does not meet coverage criteria and will be denied.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1Explicit non-covered indication

4CPT/HCPCS codes referenced

3Procedures described

Coverage Criteria

Not Medically Necessary / Not Covered

Not covered when ALL of the following are met:

Primary exclusion: Cytologic analysis of epithelial cells to assess breast cancer risk and manage patients at high risk of breast cancer DOES NOT MEET COVERAGE CRITERIA.

Based on lack of published scientific literature confirming clinical utility for diagnosis and treatment

Cytologic analysis of epithelial cells to assess breast cancer risk and to manage patients at high risk of breast cancer does not meet coverage criteria. This exclusion is based on a lack of published scientific literature demonstrating that the test is required and beneficial for diagnosis or treatment.

Cytologic analysis of epithelial cells for breast cancer risk assessment is considered not medically necessary and therefore not covered under this policy. Decisions are made on the basis that available evidence does not establish clinical utility for this indication.

Coding and Billing

Applicable CPT Codes (referenced)CPT

88108	Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique)
88112	Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal
88172	Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site
88173	Cytopathology, evaluation of fine needle aspirate; interpretation and report
88177	Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyEpithelial Cell Cytology in Breast Cancer Risk Assessment

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDo not submit prior authorization for cytologic analysis to assess breast cancer risk — this indication does not meet coverage criteria and will be denied.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Administrative Notes

Prior Authorization

Prior Authorization Expectation for Epithelial Cell Cytology

Prior authorization may be required for procedures involving epithelial cell cytology (e.g., nipple aspiration, ductal lavage, fine needle aspirate cytology). Providers should verify member benefit coverage and obtain any required prior authorization before performing these services to avoid claim denials.

Verify member-specific benefits and prior authorization requirements prior to service.
If required, submit prior authorization with clinical indication and relevant documentation (history, imaging, physical exam findings).

Step Therapy

No step therapy or step edit requirements are described for epithelial cell cytology in this policy. Providers do not need to follow a step-therapy sequence for these procedures under this policy; however member benefit design may vary and should be confirmed.

Documentation Required

Government Policy Precedence and Documentation

If a government program (Medicare or Medicaid) has applicable coverage determinations (e.g., LCDs or NCDs) that conflict with this policy, the applicable government policy takes precedence. Providers should reference the Medicare Coverage Database and state Medicaid resources for the most current guidance.

When submitting prior authorization or claims for Medicare/Medicaid members, include documentation cited by the applicable government determination (e.g., LCD/NCD references, supporting clinical notes, imaging).
If there is a conflict between this policy and a government policy for a specific member, follow the government policy.

Denial Risk

Denial Risk for Breast Cancer Risk Assessment

Cytologic analysis of epithelial cells to assess breast cancer risk and to manage patients at high risk of breast cancer is listed as not meeting coverage criteria in this policy. Submissions for such indications carry a higher risk of denial.

Denial risk is elevated when cytology is used solely to assess breast cancer risk or to manage high-risk patients; document alternative clinical justification if applicable.
Include supporting diagnostic information (e.g., suspicious mass, imaging findings) when arguing medical necessity for cytologic testing.

Definitions

inv-10: Nipple aspiration / ductal lavage — short definition and clinical context

DefinitionNon-invasive techniques to collect epithelial cells from the breast ducts for cytologic examination (nipple aspiration and ductal lavage).

Clinical useUsed to aid evaluation of nipple discharge and assess breast cancer risk.

Relation to other proceduresMay be considered alongside other diagnostic evaluations of nipple discharge; does not replace tissue biopsy when indicated.

Evidence notePolicy cites lack of sufficient published evidence supporting cytologic analysis of epithelial cells for breast cancer risk assessment (see coverage stance).

inv-11: Fine needle aspiration (FNA) — definition and sensitivity/specificity note

DefinitionMinimally invasive sampling technique using a fine needle to aspirate cells from a suspicious breast mass for cytologic evaluation (Fine Needle Aspiration, FNA).

Diagnostic performanceFNA can be used for initial diagnosis of a suspicious breast mass, but core biopsy is superior in sensitivity, specificity, and accurate histologic grading.

Clinical roleUseful as an initial, less invasive diagnostic modality; may be complemented or supplanted by core biopsy for definitive diagnosis and grading.

OpenPayer

Epithelial Cell Cytology in Breast Cancer Risk Assessment

Coverage Criteria

Coding and Billing

Provider Actions and Administrative Notes

Background

Definitions